Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Accumulated Expenses for 14 consecutive years, with $32.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 681.36% year-over-year to $32.0 million, compared with a TTM value of $32.0 million through Dec 2025, up 681.36%, and an annual FY2025 reading of $6.5 million, down 81.23% over the prior year.
  • Accumulated Expenses was $32.0 million for Q4 2025 at Enanta Pharmaceuticals, up from $6.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $34.5 million in Q3 2024 and bottomed at $3.0 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $13.8 million, with a median of $6.5 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 1089.26% in 2021, then crashed 85.22% in 2025.
  • Year by year, Accumulated Expenses stood at $26.6 million in 2021, then tumbled by 42.95% to $15.2 million in 2022, then plummeted by 71.58% to $4.3 million in 2023, then decreased by 5.03% to $4.1 million in 2024, then skyrocketed by 681.36% to $32.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for ENTA at $32.0 million in Q4 2025, $6.5 million in Q3 2025, and $4.8 million in Q2 2025.